Glancy Prongay & Murray Commences Investigation on Behalf of Seres Therapeutics, Inc. Investors
October 07 2016 - 1:17PM
Business Wire
Glancy Prongay & Murray LLP (“GPM”) announces an
investigation on behalf of investors of Seres Therapeutics, Inc.
(“Seres” or the “Company”) (NASDAQ: MCRB) concerning the Company
and its officers’ possible violations of federal securities laws.
GPM is preparing a lawsuit on behalf of injured investors.
Seres is a microbiome therapeutics platform company that focuses
on the development of biological drugs designed to restore health
by repairing the function of a dysbiotic microbiome.
On July 29, 2016, Seres disclosed that its Phase 2 clinical
study for ECOSPOR™ did not meet its primary endpoint of reducing
the relative risk of Clostridium difficle infection recurrence. On
this news, Seres shares fell sharply, as much as 76%, on August 1,
2016.
Additionally, just a couple days prior to this announcement, the
Company’s President, CEO and Chairman of the Board sold 20,000
shares of Seres at $35 per share, and another Company insider sold
38,064 shares at $35.12 per share.
If you purchased Seres securities, have information or would
like to learn more about these claims, or have any questions
concerning this announcement or your rights or interests with
respect to these matters, please contact Lesley Portnoy, Esquire,
of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California
90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to
shareholders@glancylaw.com, or visit our website at
http://www.glancylaw.com. If you inquire by email please include
your mailing address, telephone number and number of shares
purchased.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161007005676/en/
Glancy Prongay & Murray LLP, Los AngelesLesley Portnoy,
310-201-9150 or
888-773-9224shareholders@glancylaw.comwww.glancylaw.com
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Apr 2023 to Apr 2024